The disclosure relates to surgical stapling devices, and more particularly, to assemblies and methods for detachably securing or retaining a staple line buttress assembly to a surgical stapling device.
Surgical stapling devices are employed by surgeons to sequentially or simultaneously apply one or more rows of fasteners, e.g., staples or two-part fasteners, to body tissue for the purpose of joining segments of body tissue together. When stapling relatively thin or fragile tissues, it is important to effectively seal the staple line against air or fluid leakage. Additionally, it is often necessary to reinforce the staple line against the tissue to inhibit tears in the tissue or pulling of the staples through the tissue. One method of inhibiting tears or pull through involves the placement of a biocompatible reinforcing material or “buttress” material, between the staples and the underlying tissue. In this method, a layer of buttress assembly is placed against the tissue and the tissue is stapled in the conventional manner.
Accordingly, new systems and methods that enable easy and efficient attachment and removal of a buttress assembly to the surgical stapling device would be desirable.
The disclosure describes a surgical stapling device including a buttress retention assembly that demonstrates a practical approach to meeting the performance requirements and overcoming usability challenges associated with detachably securing a buttress assembly to a surgical stapling device.
In accordance with the disclosure, a surgical stapling device includes a tool assembly and a buttress assembly. The tool assembly includes first and second jaw members that are transitionable between closed and open configurations. At least one of the first or second jaw members includes a retention assembly including a support defining a recess. The buttress assembly includes a buttress material and a spine. The buttress material includes first and second portions. The spine includes an elongate portion extending along a length of the first and second portions of the buttress material and an engaging portion attached to the elongate portion in an orthogonal relation. The engaging portion is detachably received in the recess of the support of the retention assembly of the at least one of the first or second jaw members.
In an aspect, the buttress material may include a living hinge that connects the first and second portions of the buttress material to each other. The living hinge may bias the first and second portions away from each other.
In another aspect, the first and second portions of the buttress material may define a V-shape profile.
In yet another aspect, the buttress material may be monolithically formed.
In still yet another aspect, the engaging portion of the spine may extend radially outwards from an end portion of the elongate portion of the spine.
In an aspect, the at least one of the first or second jaw members may have a tapered end, and the support of the retention assembly may be disposed on the tapered end.
In another aspect, the support of the retention assembly may have a triangular shape to reduce bending of the buttress material and the spine.
In yet another aspect, the elongate portion of the spine may extend along a peripheral portion of the buttress material.
In still yet another aspect, the engaging portion of the buttress assembly may be releasably secured to the support of the retention assembly by snap fit or friction fit.
In still yet another aspect, the spine of the buttress material may be bioabsorbable.
In still yet another aspect, at least a portion of the elongate portion of the spine may be interposed between the buttress material and the first or second jaw members.
In accordance with another aspect of the disclosure, a surgical kit includes a buttress assembly, a loading assembly, and a surgical stapling device. The buttress assembly includes a buttress material and a first spine. The buttress material includes first and second portions. The first spine includes an elongate portion extending along a length of the first and second portions of the buttress material and engaging portions extending laterally outwards from respective distal end portions of the elongate portion. The loading assembly includes a base portion and an extension extending from the base portion. The base portion includes first and second anchoring assemblies on opposite ends of the base portion. The buttress assembly includes a portion that is wrapped around the extension of the loading assembly. The engaging portions of the first spine of the buttress assembly is detachably secured to the respective first and second anchoring assemblies of the base portion of the loading assembly. The surgical stapling device includes a tool assembly having first and second jaw members that are transitionable between closed and open configurations. The first or second jaw members includes respective retention assemblies. Each retention assembly includes a support defining a recess configured to releasably receive a corresponding engaging portion of the first spine.
In an aspect, the buttress material may further include a living hinge interconnecting the first and second portions of the buttress material. The living hinge may bias the first and second portions away from each other.
In another aspect, the buttress material may be monolithically formed as a single construct.
In yet another aspect, the engaging portions of the first spine may extend from the respective distal end portions of the elongate portion in an orthogonal relation.
In still yet another aspect, the buttress assembly supported on the loading assembly may define a first angle. The first and jaw members may define a second angle in the spaced apart configuration. The first and second angles may be equal.
In still yet another aspect, the buttress assembly may further include a second spine. The first and second spine may be laterally spaced apart and disposed on opposite lateral sides of the buttress material.
In an aspect, the retention assembly of the first or second jaw members may include a pair of supports defining recesses.
In another aspect, the first or second spines may be formed of a bioabsorbable material.
In yet another aspect, the support of the retention assembly of the surgical stapling device may secure the spine thereto by snap fit or interference fit.
The above and other aspects and features of this disclosure will become more apparent in view of the following detailed description when taken in conjunction with the accompanying drawings wherein like reference numerals identify similar or identical elements.
The surgical stapling device including a buttress retention assembly disclosed herein is described in detail with reference to the drawings, in which like reference numerals designate identical or corresponding elements in each of the several views. As used herein, the term “distal” refers to the portion that is being described which is farther from a user in a conventional use of the surgical stapling device, while the term “proximal” refers to the portion that is being described which is closer to a user in a conventional use of the surgical stapling device. In addition, the terms parallel and perpendicular are understood to include relative configurations that are substantially parallel and substantially perpendicular up to about + or −10 degrees from true parallel and true perpendicular. Further, to the extent consistent, any or all of the aspects detailed herein may be used in conjunction with any or all of the other aspects detailed herein.
With reference to
With continued reference to
The buttress assembly 300 is detachably securable to the tool assembly 107. To this end, the first and second jaws members 108, 110 include respective first and second retention assemblies 180, 190, as shown in
Under such a configuration, the buttress assembly 300 is wrapped around the extension 650, and the distal ends 312a, 316a of the buttress material 310 are detachably secured to the respective anchoring portions 620, 630. When the buttress assembly 300 is supported on the loading assembly 600, the first and second portions 312, 316 of the buttress assembly 300 define an angle α (
As shown in
It is further contemplated that the buttress assembly 300 may be made from any biocompatible natural or synthetic material. The material from which the buttress assembly 300 is formed may be bioabsorbable or non-bioabsorbable. It should be understood that any combination of natural, synthetic, bioabsorbable and non-bioabsorbable materials may be used to form the buttress assembly 300.
Some non-limiting examples of materials from which the buttress assembly 300 may be made include but are not limited to poly(lactic acid), poly (glycolic acid), poly (hydroxybutyrate), poly (phosphazine), polyesters, polyethylene glycols, polyethylene oxides, polyacrylamides, polyhydroxyethylmethylacrylate, polyvinylpyrrolidone, polyvinyl alcohols, polyacrylic acid, polyacetate, polycaprolactone, polypropylene, aliphatic polyesters, glycerols, poly(amino acids), copoly (ether-esters), polyalkylene oxalates, polyamides, poly (iminocarbonates), polyalkylene oxalates, polyoxaesters, polyorthoesters, polyphosphazenes and copolymers, block copolymers, homopolymers, blends and combinations thereof.
In aspects, natural biological polymers are used in forming the buttress assembly 300. Suitable natural biological polymers include, but are not limited to, collagen, gelatin, fibrin, fibrinogen, elastin, keratin, albumin, hydroxyethyl cellulose, cellulose, hydroxypropyl cellulose, carboxyethyl cellulose, chitan, chitosan, and combinations thereof. In addition, the natural biological polymers may be combined with any of the other polymeric materials described herein to produce the buttress assembly 300.
The buttress assembly 300 may be porous or non-porous, or combinations of porous and non-porous layers. Where the buttress assembly 300 is non-porous, the buttress assembly 300 may retard or inhibit tissue ingrowth from surrounding tissues thereby acting as an adhesion barrier and inhibiting the formation of unwanted scar tissue. Thus, in aspects, the buttress assembly 300 possesses anti-adhesion properties. Techniques for forming non-porous layers from such materials are within the purview of those skilled in the art and include, for example, casting, molding, and the like.
In aspects, the buttress assembly 300 is porous and possesses hemostatic properties. Where the buttress assembly 300 is porous, it has openings or pores over at least a portion of a surface thereof. Suitable materials for forming the porous layer include, but are not limited to foams (e.g., open or closed cell foams). In aspects, the pores may be in sufficient number and size so as to interconnect across the entire thickness of the porous layer. In other aspects, the pores do not interconnect across the entire thickness of the porous layer. In yet other aspects, the pores do not extend across the entire thickness of the porous layer, but rather are present at a portion of the surface thereof. In aspects, the openings or pores are located on a portion of the surface of the porous layer, with other portions of the porous layer having a non-porous texture. Those skilled in the art reading the disclosure will envision other pore distribution patterns and configurations for the porous layer.
Where the buttress assembly 300 is porous, the pores may be formed using any method suitable to forming a foam or sponge including, but not limited to the lyophilization or freeze-drying of a composition. Suitable techniques for making foams are within the purview of those skilled in the art. Porous buttress assembly 300 can be at least 0.2 cm thick, in aspects from about 0.3 to about 1.5 cm thick. Porous buttress assembly 300 can have a density of not more than about 75 mg/cm2 and, in aspects below about 20 mg/cm2. The size of the pores in the porous buttress assembly 300 can be from about 20 μm to about 300 μm, and in certain aspects from about 100 μm to about 200 μm.
The buttress assembly 300 may also include a reinforcement member. The reinforcement member may be associated with a porous or non-porous layer or may be positioned between a non-porous layer and a porous layer of the buttress assembly 300. Alternatively, the reinforcement member may be positioned entirely within one or more of the individual layers (e.g., embedded within the porous layer, the non-porous layer, or both) of the buttress assembly 300. It is also envisioned that the reinforcement member may be positioned at the surface of one of the layers making up the buttress assembly 300 and, in aspects, may be positioned at an exterior surface of the buttress assembly 300.
Some suitable non-limiting examples of reinforcement members include fabrics, meshes, monofilaments, multifilament braids, chopped fibers (sometimes referred to in the art as staple fibers) and combinations thereof. Where the reinforcement member is a mesh, it may be prepared using any technique known to those skilled in the art, such as knitting, weaving, tatting, knipling, or the like. Where monofilaments or multifilament braids are used as the reinforcement member, the monofilaments or multifilament braids may be oriented in any desired manner. For example, the monofilaments or multifilament braids may be randomly positioned with respect to each other within the buttress assembly 300. As another example, the monofilaments or multifilament braids may be oriented in a common direction within the buttress assembly 300. Where chopped fibers are used as the reinforcement member, the chopped fibers may be oriented in any desired manner. For example, the chopped fibers may be randomly oriented or may be oriented in a common direction. The chopped fibers can thus form a non-woven material, such as a mat or a felt. The chopped fibers may be joined together (e.g., by heat fusing) or they may be unattached to each other. The chopped fibers may be of any suitable length. For example, the chopped fibers may be from 0.1 mm to 100 mm in length, and in some aspects, 0.4 mm to 50 mm in length. In an aspect, the buttress assembly 300 has randomly oriented chopped fibers that have not been previously fused together and are embedded within in the buttress assembly 300.
It is envisioned that the reinforcement member may be formed from any bioabsorbable, non-bioabsorbable, natural, or synthetic material previously described herein and combinations thereof. Where monofilaments or multifilament braids are used as the reinforcement member, any commercially available suture material may advantageously be employed as the reinforcement member.
In aspects, at least one bioactive agent may be combined with the buttress assembly 300 and/or any of the individual components (the porous layer, the non-porous layer and/or the reinforcement member) used to construct the buttress assembly 300. In aspects, the buttress assembly 300 can also serve as a vehicle for delivery of the bioactive agent. The term “bioactive agent”, as used herein, is used in its broadest sense and includes any substance or mixture of substances that have clinical use. Consequently, bioactive agents may or may not have pharmacological activity per se, e.g., a dye, or fragrance. Alternatively, a bioactive agent could be any agent which provides a therapeutic or prophylactic effect such as a compound that affects or participates in tissue growth, cell growth, or cell differentiation.
Examples of classes of bioactive agents which may be utilized in accordance with the disclosure include anti-adhesives, antimicrobials, analgesics, antipyretics, anesthetics, antiepileptics, antihistamines, anti-inflammatories, cardiovascular drugs, diagnostic agents, sympathomimetics, cholinomimetics, antimuscarinics, antispasmodics, hormones, growth factors, muscle relaxants, adrenergic neuron blockers, antineoplastics, immunogenic agents, immunosuppressants, gastrointestinal drugs, diuretics, steroids, lipids, lipopolysaccharides, polysaccharides, and enzymes. It is also intended that combinations of bioactive agents may be used.
Anti-adhesive or anti-adhesion agents can be used to inhibit adhesions from forming between the buttress assembly 300 and the surrounding tissues opposite the target tissue. Some examples of these agents include, but are not limited to poly (vinyl pyrrolidone), carboxymethyl cellulose, hyaluronic acid, polyethylene oxide, poly vinyl alcohols and combinations thereof.
Suitable antimicrobial agents which may be included as a bioactive agent in the buttress assembly 300 of the disclosure include triclosan, also known as 2,4,4′-trichloro-2′-hydroxydiphenyl ether, chlorhexidine and its salts, including chlorhexidine acetate, chlorhexidine gluconate, chlorhexidine hydrochloride, and chlorhexidine sulfate, silver and its salts, including silver acetate, silver benzoate, silver carbonate, silver citrate, silver iodate, silver iodide, silver lactate, silver laurate, silver nitrate, silver oxide, silver palmitate, silver protein, and silver sulfadiazine, polymyxin, tetracycline, aminoglycosides, such as tobramycin and gentamicin, rifampicin, bacitracin, neomycin, chloramphenicol, miconazole, quinolones such as oxolinic acid, norfloxacin, nalidixic acid, pefloxacin, enoxacin and ciprofloxacin, penicillins such as oxacillin and pipracil, nonoxynol 9, fusidic acid, cephalosporins, and combinations thereof. In addition, antimicrobial proteins and peptides such as bovine lactoferrin and lactoferricin B may be included as a bioactive agent in the bioactive coating of the disclosure.
Other bioactive agents which may be included as a bioactive agent in the buttress assembly 300 in accordance with the disclosure include: local anesthetics; non-steroidal antifertility agents; parasympathomimetic agents; psychotherapeutic agents; tranquilizers; decongestants; sedative hypnotics; steroids; sulfonamides; sympathomimetic agents; vaccines; vitamins; antimalarials; anti-migraine agents; anti-parkinson agents such as L-dopa; anti-spasmodics; anticholinergic agents (e.g. oxybutynin); antitussives; bronchodilators; cardiovascular agents such as coronary vasodilators and nitroglycerin; alkaloids; analgesics; narcotics such as codeine, dihydrocodeinone, meperidine, morphine and the like; non-narcotics such as salicylates, aspirin, acetaminophen, d-propoxyphene and the like; opioid receptor antagonists, such as naltrexone and naloxone; anti-cancer agents; anti-convulsants; anti-emetics; antihistamines; anti-inflammatory agents such as hormonal agents, hydrocortisone, prednisolone, prednisone, non-hormonal agents, allopurinol, indomethacin, phenylbutazone and the like; prostaglandins and cytotoxic drugs; estrogens; antibacterials; antibiotics; anti-fungals; anti-virals; anticoagulants; anticonvulsants; antidepressants; antihistamines; and immunological agents.
Other examples of suitable bioactive agents which may be included in the coating composition include viruses and cells, peptides, polypeptides and proteins, analogs, muteins, and active fragments thereof, such as immunoglobulins, antibodies, cytokines (e.g. lymphokines, monokines, chemokines), blood clotting factors, hemopoietic factors, interleukins (IL-2, IL-3, IL-4, IL-6), interferons (β-IFN, (α-IFN and γ-IFN), erythropoietin, nucleases, tumor necrosis factor, colony stimulating factors (e.g., GCSF, GM-CSF, MC SF), insulin, anti-tumor agents and tumor suppressors, blood proteins, gonadotropins (e.g., FSH, LH, CG, etc.), hormones and hormone analogs (e.g., growth hormone), vaccines (e.g., tumoral, bacterial and viral antigens); somatostatin; antigens; blood coagulation factors; growth factors (e.g., nerve growth factor, insulin-like growth factor); protein inhibitors, protein antagonists, and protein agonists; nucleic acids, such as antisense molecules, DNA and RNA; oligonucleotides; polynucleotides; and ribozymes.
While the disclosure has been shown in the drawings, it is not intended that the disclosure be limited thereto, as it is intended that the disclosure be as broad in scope as the art will allow and that the specification be read likewise. Therefore, the above description should not be construed as limiting, but merely as exemplifications. Those skilled in the art will envision other modifications within the scope and spirit of the claims appended hereto.
Number | Name | Date | Kind |
---|---|---|---|
3054406 | Usher | Sep 1962 | A |
3124136 | Usher | Mar 1964 | A |
3364200 | Ashton et al. | Jan 1968 | A |
3499591 | Green | Mar 1970 | A |
3797494 | Zaffaroni | Mar 1974 | A |
3939068 | Wendt et al. | Feb 1976 | A |
3948666 | Kitanishi et al. | Apr 1976 | A |
4064062 | Yurko | Dec 1977 | A |
4166800 | Fong | Sep 1979 | A |
4282236 | Broom | Aug 1981 | A |
4347847 | Usher | Sep 1982 | A |
4354628 | Green | Oct 1982 | A |
4416698 | McCorsley, III | Nov 1983 | A |
4429695 | Green | Feb 1984 | A |
4452245 | Usher | Jun 1984 | A |
4605730 | Shalaby et al. | Aug 1986 | A |
4626253 | Broadnax, Jr. | Dec 1986 | A |
4655221 | Devereux | Apr 1987 | A |
4834090 | Moore | May 1989 | A |
4838884 | Dumican et al. | Jun 1989 | A |
4927640 | Dahlinder et al. | May 1990 | A |
4930674 | Barak | Jun 1990 | A |
5002551 | Linsky et al. | Mar 1991 | A |
5014899 | Presty et al. | May 1991 | A |
5040715 | Green et al. | Aug 1991 | A |
5057334 | Vail | Oct 1991 | A |
5065929 | Schulze et al. | Nov 1991 | A |
5112496 | Dhawan et al. | May 1992 | A |
5162430 | Rhee et al. | Nov 1992 | A |
5205459 | Brinkerhoff et al. | Apr 1993 | A |
5263629 | Trumbull et al. | Nov 1993 | A |
5281197 | Arias et al. | Jan 1994 | A |
5307976 | Olson et al. | May 1994 | A |
5312023 | Green et al. | May 1994 | A |
5314471 | Brauker et al. | May 1994 | A |
5318221 | Green et al. | Jun 1994 | A |
5324775 | Rhee et al. | Jun 1994 | A |
5326013 | Green et al. | Jul 1994 | A |
5332142 | Robinson et al. | Jul 1994 | A |
5344454 | Clarke et al. | Sep 1994 | A |
5392979 | Green et al. | Feb 1995 | A |
5397324 | Carroll et al. | Mar 1995 | A |
5405072 | Zlock et al. | Apr 1995 | A |
5410016 | Hubbell et al. | Apr 1995 | A |
5425745 | Green et al. | Jun 1995 | A |
5441193 | Gravener | Aug 1995 | A |
5441507 | Wilk | Aug 1995 | A |
5443198 | Viola et al. | Aug 1995 | A |
5468253 | Bezwada et al. | Nov 1995 | A |
5484913 | Stilwell et al. | Jan 1996 | A |
5503638 | Cooper et al. | Apr 1996 | A |
5514379 | Weissleder et al. | May 1996 | A |
5542594 | McKean et al. | Aug 1996 | A |
5543441 | Rhee et al. | Aug 1996 | A |
5549628 | Cooper et al. | Aug 1996 | A |
5550187 | Rhee et al. | Aug 1996 | A |
5575803 | Cooper et al. | Nov 1996 | A |
5645915 | Kranzler et al. | Jul 1997 | A |
5653756 | Clarke et al. | Aug 1997 | A |
5683809 | Freeman et al. | Nov 1997 | A |
5690675 | Sawyer et al. | Nov 1997 | A |
5702409 | Raybum et al. | Dec 1997 | A |
5752965 | Francis et al. | May 1998 | A |
5752974 | Rhee et al. | May 1998 | A |
5762256 | Mastri et al. | Jun 1998 | A |
5766188 | Igaki | Jun 1998 | A |
5769892 | Kingwell | Jun 1998 | A |
5782396 | Mastri et al. | Jul 1998 | A |
5799857 | Robertson et al. | Sep 1998 | A |
5810855 | Rayburn et al. | Sep 1998 | A |
5814057 | Oi et al. | Sep 1998 | A |
5819350 | Wang | Oct 1998 | A |
5833695 | Yoon | Nov 1998 | A |
5843096 | Igaki et al. | Dec 1998 | A |
5871135 | Williamson, IV et al. | Feb 1999 | A |
5874500 | Rhee et al. | Feb 1999 | A |
5895412 | Tucker | Apr 1999 | A |
5895415 | Chow et al. | Apr 1999 | A |
5902312 | Frater et al. | May 1999 | A |
5908427 | McKean et al. | Jun 1999 | A |
5915616 | Viola et al. | Jun 1999 | A |
5931847 | Bittner et al. | Aug 1999 | A |
5957363 | Heck | Sep 1999 | A |
5964774 | McKean et al. | Oct 1999 | A |
5997895 | Narotam et al. | Dec 1999 | A |
6019791 | Wood | Feb 2000 | A |
6030392 | Dakov | Feb 2000 | A |
6032849 | Mastri et al. | Mar 2000 | A |
6045560 | McKean et al. | Apr 2000 | A |
6063097 | Oi et al. | May 2000 | A |
6080169 | Turtel | Jun 2000 | A |
6093557 | Pui et al. | Jul 2000 | A |
6099551 | Gabbay | Aug 2000 | A |
6142933 | Longo et al. | Nov 2000 | A |
6149667 | Hovland et al. | Nov 2000 | A |
6152943 | Sawhney | Nov 2000 | A |
6155265 | Hammerslag | Dec 2000 | A |
6156677 | Brown Reed et al. | Dec 2000 | A |
6165201 | Sawhney et al. | Dec 2000 | A |
6179862 | Sawhney | Jan 2001 | B1 |
6210439 | Firmin et al. | Apr 2001 | B1 |
6214020 | Mulhauser et al. | Apr 2001 | B1 |
6241139 | Milliman et al. | Jun 2001 | B1 |
6258107 | Balazs et al. | Jul 2001 | B1 |
6267772 | Mulhauser et al. | Jul 2001 | B1 |
6270530 | Eldridge et al. | Aug 2001 | B1 |
6273897 | Dalessandro et al. | Aug 2001 | B1 |
6280453 | Kugel et al. | Aug 2001 | B1 |
6299631 | Shalaby | Oct 2001 | B1 |
6309569 | Farrar et al. | Oct 2001 | B1 |
6312457 | DiMatteo et al. | Nov 2001 | B1 |
6312474 | Francis et al. | Nov 2001 | B1 |
6325810 | Hamilton et al. | Dec 2001 | B1 |
6330965 | Milliman et al. | Dec 2001 | B1 |
6399362 | Pui et al. | Jun 2002 | B1 |
6436030 | Rehil | Aug 2002 | B2 |
6454780 | Wallace | Sep 2002 | B1 |
6461368 | Fogarty et al. | Oct 2002 | B2 |
6500777 | Wiseman et al. | Dec 2002 | B1 |
6503257 | Grant et al. | Jan 2003 | B2 |
6514283 | DiMatteo et al. | Feb 2003 | B2 |
6514534 | Sawhney | Feb 2003 | B1 |
6517566 | Hovland et al. | Feb 2003 | B1 |
6551356 | Rousseau | Apr 2003 | B2 |
6566406 | Pathak et al. | May 2003 | B1 |
6568398 | Cohen | May 2003 | B2 |
6590095 | Schleicher et al. | Jul 2003 | B1 |
6592597 | Grant et al. | Jul 2003 | B2 |
6605294 | Sawhney | Aug 2003 | B2 |
6610006 | Amid et al. | Aug 2003 | B1 |
6627749 | Kumar | Sep 2003 | B1 |
6638285 | Gabbay | Oct 2003 | B2 |
6652594 | Francis et al. | Nov 2003 | B2 |
6656193 | Grant et al. | Dec 2003 | B2 |
6656200 | Li et al. | Dec 2003 | B2 |
6669735 | Pelissier | Dec 2003 | B1 |
6673093 | Sawhney | Jan 2004 | B1 |
6677258 | Carroll et al. | Jan 2004 | B2 |
6685714 | Rousseau | Feb 2004 | B2 |
6702828 | Whayne | Mar 2004 | B2 |
6703047 | Sawhney et al. | Mar 2004 | B2 |
6704210 | Myers | Mar 2004 | B1 |
6723114 | Shalaby | Apr 2004 | B2 |
6726706 | Dominguez | Apr 2004 | B2 |
6736823 | Darois et al. | May 2004 | B2 |
6736854 | Vadurro et al. | May 2004 | B2 |
6746458 | Cloud | Jun 2004 | B1 |
6746869 | Pui et al. | Jun 2004 | B2 |
6764720 | Pui et al. | Jul 2004 | B2 |
6773458 | Brauker et al. | Aug 2004 | B1 |
6818018 | Sawhney | Nov 2004 | B1 |
6843252 | Harrison et al. | Jan 2005 | B2 |
6896684 | Monassevitch et al. | May 2005 | B2 |
6927315 | Heinecke et al. | Aug 2005 | B1 |
6939358 | Palacios et al. | Sep 2005 | B2 |
6946196 | Foss | Sep 2005 | B2 |
6953139 | Milliman et al. | Oct 2005 | B2 |
6959851 | Heinrich | Nov 2005 | B2 |
7009034 | Pathak et al. | Mar 2006 | B2 |
7025772 | Gellman et al. | Apr 2006 | B2 |
7060087 | DiMatteo et al. | Jun 2006 | B2 |
7087065 | Ulmsten et al. | Aug 2006 | B2 |
7108701 | Evens et al. | Sep 2006 | B2 |
7128253 | Mastri et al. | Oct 2006 | B2 |
7128748 | Mooradian et al. | Oct 2006 | B2 |
7134438 | Makower et al. | Nov 2006 | B2 |
7141055 | Abrams et al. | Nov 2006 | B2 |
7147138 | Shelton, IV | Dec 2006 | B2 |
7160299 | Baily | Jan 2007 | B2 |
7179268 | Roy et al. | Feb 2007 | B2 |
7210810 | Iversen et al. | May 2007 | B1 |
7214727 | Kwon et al. | May 2007 | B2 |
7232449 | Sharkawy et al. | Jun 2007 | B2 |
7241300 | Sharkawy et al. | Jul 2007 | B2 |
7247338 | Pui et al. | Jul 2007 | B2 |
7279322 | Pui et al. | Oct 2007 | B2 |
7307031 | Carroll et al. | Dec 2007 | B2 |
7308998 | Mastri et al. | Dec 2007 | B2 |
7311720 | Mueller et al. | Dec 2007 | B2 |
7328829 | Arad et al. | Feb 2008 | B2 |
7334717 | Rethy et al. | Feb 2008 | B2 |
7347850 | Sawhney | Mar 2008 | B2 |
7377928 | Zubik et al. | May 2008 | B2 |
7434717 | Shelton, IV et al. | Oct 2008 | B2 |
7438209 | Hess et al. | Oct 2008 | B1 |
7464849 | Shelton, IV et al. | Dec 2008 | B2 |
7498063 | Pui et al. | Mar 2009 | B2 |
7547312 | Bauman et al. | Jun 2009 | B2 |
7559937 | de la Torre et al. | Jul 2009 | B2 |
7571845 | Viola | Aug 2009 | B2 |
7592418 | Pathak et al. | Sep 2009 | B2 |
7594921 | Browning | Sep 2009 | B2 |
7595392 | Kumar et al. | Sep 2009 | B2 |
7604151 | Hess et al. | Oct 2009 | B2 |
7611494 | Campbell et al. | Nov 2009 | B2 |
7635073 | Heinrich | Dec 2009 | B2 |
7645874 | Saferstein et al. | Jan 2010 | B2 |
7649089 | Kumar et al. | Jan 2010 | B2 |
7655288 | Bauman et al. | Feb 2010 | B2 |
7662409 | Masters | Feb 2010 | B2 |
7662801 | Kumar et al. | Feb 2010 | B2 |
7665646 | Prommersberger | Feb 2010 | B2 |
7666198 | Suyker et al. | Feb 2010 | B2 |
7669747 | Weisenburgh, II et al. | Mar 2010 | B2 |
7673782 | Hess et al. | Mar 2010 | B2 |
7708180 | Murray et al. | May 2010 | B2 |
7709631 | Harris et al. | May 2010 | B2 |
7717313 | Criscuolo et al. | May 2010 | B2 |
7722642 | Williamson, IV et al. | May 2010 | B2 |
7735703 | Morgan et al. | Jun 2010 | B2 |
7744627 | Orban, III et al. | Jun 2010 | B2 |
7754002 | Maase et al. | Jul 2010 | B2 |
7776060 | Mooradian et al. | Aug 2010 | B2 |
7789889 | Zubik et al. | Sep 2010 | B2 |
7793813 | Bettuchi | Sep 2010 | B2 |
7799026 | Schechter et al. | Sep 2010 | B2 |
7819896 | Racenet | Oct 2010 | B2 |
7823592 | Bettuchi et al. | Nov 2010 | B2 |
7824420 | Eldridge et al. | Nov 2010 | B2 |
7845533 | Marczyk et al. | Dec 2010 | B2 |
7845536 | Viola et al. | Dec 2010 | B2 |
7846149 | Jankowski | Dec 2010 | B2 |
7892247 | Conston et al. | Feb 2011 | B2 |
7909224 | Prommersberger | Mar 2011 | B2 |
7909837 | Crews et al. | Mar 2011 | B2 |
7938307 | Bettuchi | May 2011 | B2 |
7942890 | D'Agostino et al. | May 2011 | B2 |
7950561 | Aranyi | May 2011 | B2 |
7951166 | Orban, III et al. | May 2011 | B2 |
7951248 | Fallis et al. | May 2011 | B1 |
7967179 | Olson et al. | Jun 2011 | B2 |
7988027 | Olson et al. | Aug 2011 | B2 |
8011550 | Aranyi et al. | Sep 2011 | B2 |
8011555 | Tarinelli et al. | Sep 2011 | B2 |
8016177 | Bettuchi et al. | Sep 2011 | B2 |
8016178 | Olson et al. | Sep 2011 | B2 |
8025199 | Whitman et al. | Sep 2011 | B2 |
8028883 | Stopek | Oct 2011 | B2 |
8033483 | Fortier et al. | Oct 2011 | B2 |
8033983 | Chu et al. | Oct 2011 | B2 |
8038045 | Bettuchi et al. | Oct 2011 | B2 |
8062330 | Prommersberger et al. | Nov 2011 | B2 |
8062673 | Figuly et al. | Nov 2011 | B2 |
8083119 | Prommersberger | Dec 2011 | B2 |
8091756 | Viola | Jan 2012 | B2 |
8123766 | Bauman et al. | Feb 2012 | B2 |
8123767 | Bauman et al. | Feb 2012 | B2 |
8127975 | Olson et al. | Mar 2012 | B2 |
8133336 | Kettlewell et al. | Mar 2012 | B2 |
8133559 | Lee et al. | Mar 2012 | B2 |
8146791 | Bettuchi et al. | Apr 2012 | B2 |
8152777 | Campbell et al. | Apr 2012 | B2 |
8157149 | Olson et al. | Apr 2012 | B2 |
8157151 | Ingmanson et al. | Apr 2012 | B2 |
8167895 | D'Agostino et al. | May 2012 | B2 |
8177797 | Shimoji et al. | May 2012 | B2 |
8178746 | Hildeberg et al. | May 2012 | B2 |
8192460 | Orban, III et al. | Jun 2012 | B2 |
8201720 | Hessler | Jun 2012 | B2 |
8210414 | Bettuchi et al. | Jul 2012 | B2 |
8210453 | Hull et al. | Jul 2012 | B2 |
8225799 | Bettuchi | Jul 2012 | B2 |
8225981 | Criscuolo et al. | Jul 2012 | B2 |
8231043 | Tarinelli et al. | Jul 2012 | B2 |
8235273 | Olson et al. | Aug 2012 | B2 |
8245901 | Stopek | Aug 2012 | B2 |
8252339 | Figuly et al. | Aug 2012 | B2 |
8252921 | Vignon et al. | Aug 2012 | B2 |
8256654 | Bettuchi et al. | Sep 2012 | B2 |
8257391 | Orban, III et al. | Sep 2012 | B2 |
8276800 | Bettuchi | Oct 2012 | B2 |
8286849 | Bettuchi | Oct 2012 | B2 |
8308042 | Aranyi | Nov 2012 | B2 |
8308045 | Bettuchi et al. | Nov 2012 | B2 |
8308046 | Prommersberger | Nov 2012 | B2 |
8312885 | Bettuchi et al. | Nov 2012 | B2 |
8313014 | Bettuchi | Nov 2012 | B2 |
8317790 | Bell et al. | Nov 2012 | B2 |
8322590 | Patel et al. | Dec 2012 | B2 |
8348126 | Olson et al. | Jan 2013 | B2 |
8348130 | Shah et al. | Jan 2013 | B2 |
8365972 | Aranyi et al. | Feb 2013 | B2 |
8367089 | Wan et al. | Feb 2013 | B2 |
8371491 | Huitema et al. | Feb 2013 | B2 |
8371492 | Aranyi et al. | Feb 2013 | B2 |
8371493 | Aranyi et al. | Feb 2013 | B2 |
8372094 | Bettuchi et al. | Feb 2013 | B2 |
8393514 | Shelton, IV et al. | Mar 2013 | B2 |
8393517 | Milo | Mar 2013 | B2 |
8408440 | Olson et al. | Apr 2013 | B2 |
8408480 | Hull et al. | Apr 2013 | B2 |
8413869 | Heinrich | Apr 2013 | B2 |
8413871 | Racenet et al. | Apr 2013 | B2 |
8418909 | Kostrzewski | Apr 2013 | B2 |
8424742 | Bettuchi | Apr 2013 | B2 |
8453652 | Stopek | Jun 2013 | B2 |
8453904 | Eskaros et al. | Jun 2013 | B2 |
8453909 | Olson et al. | Jun 2013 | B2 |
8453910 | Bettuchi et al. | Jun 2013 | B2 |
8464925 | Hull et al. | Jun 2013 | B2 |
8470360 | McKay | Jun 2013 | B2 |
8474677 | Woodard, Jr. et al. | Jul 2013 | B2 |
8479968 | Hodgkinson et al. | Jul 2013 | B2 |
8485414 | Criscuolo et al. | Jul 2013 | B2 |
8496683 | Prommersberger et al. | Jul 2013 | B2 |
8511533 | Viola et al. | Aug 2013 | B2 |
8512402 | Marczyk et al. | Aug 2013 | B2 |
8518440 | Blaskovich et al. | Aug 2013 | B2 |
8529600 | Woodard, Jr. et al. | Sep 2013 | B2 |
8540128 | Shelton, IV et al. | Sep 2013 | B2 |
8540131 | Swayze | Sep 2013 | B2 |
8551138 | Orban, III et al. | Oct 2013 | B2 |
8556918 | Bauman et al. | Oct 2013 | B2 |
8561873 | Ingmanson et al. | Oct 2013 | B2 |
8579990 | Priewe | Nov 2013 | B2 |
8584920 | Hodgkinson | Nov 2013 | B2 |
8590762 | Hess et al. | Nov 2013 | B2 |
8616430 | (Prommersberger) Stopek et al. | Dec 2013 | B2 |
8617132 | Golzarian et al. | Dec 2013 | B2 |
8631989 | Aranyi et al. | Jan 2014 | B2 |
8646674 | Schulte et al. | Feb 2014 | B2 |
8668129 | Olson | Mar 2014 | B2 |
8678263 | Viola | Mar 2014 | B2 |
8679137 | Bauman et al. | Mar 2014 | B2 |
8684250 | Bettuchi et al. | Apr 2014 | B2 |
8701958 | Shelton, IV et al. | Apr 2014 | B2 |
8721703 | Fowler | May 2014 | B2 |
8727197 | Hess et al. | May 2014 | B2 |
8757466 | Olson et al. | Jun 2014 | B2 |
8789737 | Hodgkinson et al. | Jul 2014 | B2 |
8814888 | Sgro | Aug 2014 | B2 |
8820606 | Hodgkinson | Sep 2014 | B2 |
8827133 | Shelton, IV et al. | Sep 2014 | B2 |
8857694 | Shelton, IV et al. | Oct 2014 | B2 |
8864009 | Shelton, IV et al. | Oct 2014 | B2 |
8870050 | Hodgkinson | Oct 2014 | B2 |
8920443 | Hiles et al. | Dec 2014 | B2 |
8920444 | Hiles et al. | Dec 2014 | B2 |
8939344 | Olson et al. | Jan 2015 | B2 |
8956390 | Shah et al. | Feb 2015 | B2 |
8967448 | Carter et al. | Mar 2015 | B2 |
9005243 | Stopek et al. | Apr 2015 | B2 |
9010606 | Aranyi et al. | Apr 2015 | B2 |
9010608 | Casasanta, Jr. et al. | Apr 2015 | B2 |
9010609 | Carter et al. | Apr 2015 | B2 |
9010610 | Hodgkinson | Apr 2015 | B2 |
9010612 | Stevenson et al. | Apr 2015 | B2 |
9016543 | (Prommersberger) Stopek et al. | Apr 2015 | B2 |
9016544 | Hodgkinson et al. | Apr 2015 | B2 |
9027817 | Milliman et al. | May 2015 | B2 |
9044227 | Shelton, IV et al. | Jun 2015 | B2 |
9055944 | Hodgkinson et al. | Jun 2015 | B2 |
9084602 | Gleiman | Jul 2015 | B2 |
9107665 | Hodgkinson et al. | Aug 2015 | B2 |
9107667 | Hodgkinson | Aug 2015 | B2 |
9113871 | Milliman et al. | Aug 2015 | B2 |
9113873 | Marczyk et al. | Aug 2015 | B2 |
9113885 | Hodgkinson et al. | Aug 2015 | B2 |
9113893 | Sorrentino et al. | Aug 2015 | B2 |
9161753 | Prior | Oct 2015 | B2 |
9161757 | Bettuchi | Oct 2015 | B2 |
9186140 | Hiles et al. | Nov 2015 | B2 |
9186144 | Stevenson et al. | Nov 2015 | B2 |
9192378 | Aranyi et al. | Nov 2015 | B2 |
9192379 | Aranyi et al. | Nov 2015 | B2 |
9192380 | (Tarinelli) Racenet et al. | Nov 2015 | B2 |
9192383 | Milliman | Nov 2015 | B2 |
9192384 | Bettuchi | Nov 2015 | B2 |
9198660 | Hodgkinson | Dec 2015 | B2 |
9198663 | Marczyk et al. | Dec 2015 | B1 |
9204881 | Penna | Dec 2015 | B2 |
9220504 | Viola et al. | Dec 2015 | B2 |
9226754 | D'Agostino et al. | Jan 2016 | B2 |
9237892 | Hodgkinson | Jan 2016 | B2 |
9237893 | Carter et al. | Jan 2016 | B2 |
9277922 | Carter et al. | Mar 2016 | B2 |
9295466 | Hodgkinson et al. | Mar 2016 | B2 |
9326768 | Shelton, IV | May 2016 | B2 |
9326773 | Casasanta, Jr. et al. | May 2016 | B2 |
9328111 | Zhou et al. | May 2016 | B2 |
9345479 | (Tarinelli) Racenet et al. | May 2016 | B2 |
9351729 | Orban, III et al. | May 2016 | B2 |
9351731 | Carter et al. | May 2016 | B2 |
9351732 | Hodgkinson | May 2016 | B2 |
9358005 | Shelton, IV et al. | Jun 2016 | B2 |
9364229 | D'Agostino et al. | Jun 2016 | B2 |
9364234 | (Prommersberger) Stopek et al. | Jun 2016 | B2 |
9386988 | Baxter, III et al. | Jul 2016 | B2 |
9402627 | Stevenson et al. | Aug 2016 | B2 |
9414839 | Penna | Aug 2016 | B2 |
9433412 | Bettuchi et al. | Sep 2016 | B2 |
9433413 | Stopek | Sep 2016 | B2 |
9433420 | Hodgkinson | Sep 2016 | B2 |
9445812 | Olson et al. | Sep 2016 | B2 |
9445817 | Bettuchi | Sep 2016 | B2 |
9463260 | Stopek | Oct 2016 | B2 |
9486215 | Olson et al. | Nov 2016 | B2 |
9492170 | Bear et al. | Nov 2016 | B2 |
9504470 | Milliman | Nov 2016 | B2 |
9517164 | Vitaris et al. | Dec 2016 | B2 |
9572576 | Hodgkinson et al. | Feb 2017 | B2 |
9585657 | Shelton, IV et al. | Mar 2017 | B2 |
9597077 | Hodgkinson | Mar 2017 | B2 |
9610080 | Whitfield et al. | Apr 2017 | B2 |
9622745 | Ingmanson et al. | Apr 2017 | B2 |
9629626 | Soltz et al. | Apr 2017 | B2 |
9636850 | Stopek (nee Prommersberger) et al. | May 2017 | B2 |
9655620 | Prescott et al. | May 2017 | B2 |
9675351 | Hodgkinson et al. | Jun 2017 | B2 |
9681936 | Hodgkinson et al. | Jun 2017 | B2 |
9687262 | Rousseau et al. | Jun 2017 | B2 |
9693772 | Ingmanson et al. | Jul 2017 | B2 |
9708184 | Chan et al. | Jul 2017 | B2 |
9770245 | Swayze et al. | Sep 2017 | B2 |
9775617 | Carter et al. | Oct 2017 | B2 |
9775618 | Bettuchi et al. | Oct 2017 | B2 |
9782173 | Mozdzierz | Oct 2017 | B2 |
9844378 | Casasanta et al. | Dec 2017 | B2 |
9918713 | Zergiebel et al. | Mar 2018 | B2 |
9931116 | Racenet et al. | Apr 2018 | B2 |
10022125 | (Prommersberger) Stopek et al. | Jul 2018 | B2 |
10098639 | Hodgkinson | Oct 2018 | B2 |
10111659 | Racenet et al. | Oct 2018 | B2 |
10154840 | Viola et al. | Dec 2018 | B2 |
20020091397 | Chen | Jul 2002 | A1 |
20020151911 | Gabbay | Oct 2002 | A1 |
20030065345 | Weadock | Apr 2003 | A1 |
20030078209 | Schmidt | Apr 2003 | A1 |
20030083676 | Wallace | May 2003 | A1 |
20030125676 | Swenson et al. | Jul 2003 | A1 |
20030181927 | Wallace | Sep 2003 | A1 |
20030208231 | Williamson et al. | Nov 2003 | A1 |
20040092912 | Jinno et al. | May 2004 | A1 |
20040107006 | Francis et al. | Jun 2004 | A1 |
20040131418 | Budde et al. | Jul 2004 | A1 |
20040254590 | Hoffman et al. | Dec 2004 | A1 |
20040260315 | Dell et al. | Dec 2004 | A1 |
20050002981 | Lahtinen et al. | Jan 2005 | A1 |
20050006429 | Wales et al. | Jan 2005 | A1 |
20050021085 | Abrams et al. | Jan 2005 | A1 |
20050059996 | Bauman et al. | Mar 2005 | A1 |
20050059997 | Bauman et al. | Mar 2005 | A1 |
20050070929 | Dalessandro et al. | Mar 2005 | A1 |
20050118435 | DeLucia et al. | Jun 2005 | A1 |
20050149073 | Arani et al. | Jul 2005 | A1 |
20050283256 | Sommerich et al. | Dec 2005 | A1 |
20060008505 | Brandon | Jan 2006 | A1 |
20060121266 | Fandel et al. | Jun 2006 | A1 |
20060173470 | Oray et al. | Aug 2006 | A1 |
20060190027 | Downey | Aug 2006 | A1 |
20070034669 | de la Torre | Feb 2007 | A1 |
20070203510 | Bettuchi | Aug 2007 | A1 |
20070243227 | Gertner | Oct 2007 | A1 |
20070246505 | Pace-Floridia et al. | Oct 2007 | A1 |
20080009811 | Cantor | Jan 2008 | A1 |
20080029570 | Shelton et al. | Feb 2008 | A1 |
20080082126 | Murray et al. | Apr 2008 | A1 |
20080140115 | Stopek | Jun 2008 | A1 |
20080169328 | Shelton | Jul 2008 | A1 |
20080169332 | Shelton et al. | Jul 2008 | A1 |
20080169333 | Shelton et al. | Jul 2008 | A1 |
20080216855 | Nasca | Sep 2008 | A1 |
20080220047 | Sawhney et al. | Sep 2008 | A1 |
20080290134 | Bettuchi et al. | Nov 2008 | A1 |
20090001121 | Hess et al. | Jan 2009 | A1 |
20090001130 | Hess et al. | Jan 2009 | A1 |
20090031842 | Kawai et al. | Feb 2009 | A1 |
20090206125 | Huitema et al. | Aug 2009 | A1 |
20090206126 | Huitema et al. | Aug 2009 | A1 |
20090206139 | Hall et al. | Aug 2009 | A1 |
20090206141 | Huitema et al. | Aug 2009 | A1 |
20090206142 | Huitema et al. | Aug 2009 | A1 |
20090218384 | Aranyi | Sep 2009 | A1 |
20090277944 | Dalessandro et al. | Nov 2009 | A9 |
20100016855 | Ramstein et al. | Jan 2010 | A1 |
20100016888 | Calabrese et al. | Jan 2010 | A1 |
20100087840 | Ebersole et al. | Apr 2010 | A1 |
20100147921 | Olson | Jun 2010 | A1 |
20100147922 | Olson | Jun 2010 | A1 |
20100174253 | Cline et al. | Jul 2010 | A1 |
20100203151 | Hiraoka | Aug 2010 | A1 |
20100243707 | Olson et al. | Sep 2010 | A1 |
20100331859 | Omori | Dec 2010 | A1 |
20110034910 | Ross et al. | Feb 2011 | A1 |
20110089220 | Ingmanson et al. | Apr 2011 | A1 |
20110125138 | Malinouskas et al. | May 2011 | A1 |
20110166673 | Patel et al. | Jul 2011 | A1 |
20110293690 | Griffin et al. | Dec 2011 | A1 |
20120080336 | Shelton, IV et al. | Apr 2012 | A1 |
20120197272 | Oray et al. | Aug 2012 | A1 |
20120241491 | Aldridge et al. | Sep 2012 | A1 |
20120241493 | Baxter, III et al. | Sep 2012 | A1 |
20120253298 | Henderson et al. | Oct 2012 | A1 |
20130153636 | Shelton, IV et al. | Jun 2013 | A1 |
20130153641 | Shelton, IV et al. | Jun 2013 | A1 |
20130256380 | Schmid et al. | Oct 2013 | A1 |
20140048580 | Merchant et al. | Feb 2014 | A1 |
20140131418 | Kostrzewski | May 2014 | A1 |
20140224686 | Aronhalt et al. | Aug 2014 | A1 |
20140239047 | Hodgkinson et al. | Aug 2014 | A1 |
20140263550 | Aranyi et al. | Sep 2014 | A1 |
20150041347 | Hodgkinson | Feb 2015 | A1 |
20150133995 | Shelton, IV et al. | May 2015 | A1 |
20150157321 | Zergiebel et al. | Jun 2015 | A1 |
20150209045 | Hodgkinson et al. | Jul 2015 | A1 |
20150231409 | Racenet et al. | Aug 2015 | A1 |
20150327864 | Hodgkinson et al. | Nov 2015 | A1 |
20160022268 | Prior | Jan 2016 | A1 |
20160045200 | Milliman | Feb 2016 | A1 |
20160100834 | Viola et al. | Apr 2016 | A1 |
20160106430 | Carter et al. | Apr 2016 | A1 |
20160128694 | Baxter, III et al. | May 2016 | A1 |
20160157857 | Hodgkinson et al. | Jun 2016 | A1 |
20160174988 | D'Agostino et al. | Jun 2016 | A1 |
20160206315 | Olson | Jul 2016 | A1 |
20160220257 | Casasanta et al. | Aug 2016 | A1 |
20160249923 | Hodgkinson et al. | Sep 2016 | A1 |
20160270793 | Carter et al. | Sep 2016 | A1 |
20160310143 | Bettuchi | Oct 2016 | A1 |
20160338704 | Penna | Nov 2016 | A1 |
20160367252 | Olson et al. | Dec 2016 | A1 |
20160367253 | Hodgkinson | Dec 2016 | A1 |
20160367257 | Stevenson et al. | Dec 2016 | A1 |
20170042540 | Olson et al. | Feb 2017 | A1 |
20170049452 | Milliman | Feb 2017 | A1 |
20170119390 | Schellin et al. | May 2017 | A1 |
20170150967 | Hodgkinson et al. | Jun 2017 | A1 |
20170172575 | Hodgkinson | Jun 2017 | A1 |
20170231629 | Stopek et al. | Aug 2017 | A1 |
20170238931 | Prescott et al. | Aug 2017 | A1 |
20170281328 | Hodgkinson, Ph.D et al. | Oct 2017 | A1 |
20170296188 | Ingmanson et al. | Oct 2017 | A1 |
20170354415 | Casasanta, Jr. et al. | Dec 2017 | A1 |
20180125491 | Aranyi | May 2018 | A1 |
20180140301 | Milliman | May 2018 | A1 |
20180168654 | Hodgkinson et al. | Jun 2018 | A1 |
20180214147 | Merchant et al. | Aug 2018 | A1 |
20180229054 | Racenet et al. | Aug 2018 | A1 |
20180250000 | Hodgkinson et al. | Sep 2018 | A1 |
20180256164 | Aranyi | Sep 2018 | A1 |
20180296214 | Hodgkinson et al. | Oct 2018 | A1 |
20180310937 | (Prommersberger) Stopek et al. | Nov 2018 | A1 |
20190021734 | Hodgkinson | Jan 2019 | A1 |
20190059878 | (Tarinelli) Racenet et al. | Feb 2019 | A1 |
20190083087 | Viola et al. | Mar 2019 | A1 |
20210177415 | Shelton, IV et al. | Jun 2021 | A1 |
Number | Date | Country |
---|---|---|
2282761 | Sep 1998 | CA |
1602563 | Mar 1950 | DE |
19924311 | Nov 2000 | DE |
0327022 | Aug 1989 | EP |
0594148 | Apr 1994 | EP |
2462880 | Jun 2012 | EP |
2491867 | Aug 2012 | EP |
3150142 | Apr 2017 | EP |
2000166933 | Jun 2000 | JP |
2002202213 | Jul 2002 | JP |
2007124166 | May 2007 | JP |
2010214132 | Sep 2010 | JP |
9005489 | May 1990 | WO |
9516221 | Jun 1995 | WO |
9838923 | Sep 1998 | WO |
9926826 | Jun 1999 | WO |
0010456 | Mar 2000 | WO |
0016684 | Mar 2000 | WO |
2010075298 | Jul 2010 | WO |
Entry |
---|
Extended European Search Report corresponding to EP 14 16 9739.1, completed Aug. 19, 2014 and dated Aug. 29, 2014; (7 pp). |
Extended European Search Report corresponding to EP 14 15 7997.9, completed Sep. 9, 2014 and dated Sep. 17, 2014; (8 pp). |
Extended European Search Report corresponding to EP 14 16 8904.2, completed Sep. 10, 2014 and dated Sep. 18, 2014; (8 pp). |
Extended European Search Report corresponding to EP 13 19 4995.0, completed Jun. 5, 2014 and dated Oct. 13, 2014; (10 pp). |
Extended European Search Report corresponding to EP 13 15 4571.7, completed Oct. 10, 2014 and dated Oct. 20, 2014; (8 pp). |
Extended European Search Report corresponding to EP 14 18 1125.7, completed Oct. 16, 2014 and dated Oct. 24, 2014; (7 pp). |
Extended European Search Report corresponding to EP 14 18 1127.3, completed Oct. 16, 2014 and dated Nov. 10, 2014; (8 pp). |
Extended European Search Report corresponding to EP 14 19 0419.3, completed Mar. 24, 2015 and dated Mar. 30, 2015; (6 pp). |
European Office Action corresponding to EP 12 198 776.2 dated Apr. 7, 2015. |
European Office Action corresponding to EP 13 156 297.7 dated Apr. 10, 2015. |
Australian Examination Report No. 1 corresponding to AU 2011250822 dated May 18, 2015. |
European Office Action corresponding to EP 12 186 175.1 dated Jun. 1, 2015. |
Chinese Office Action corresponding to CN 201010517292.8 dated Jun. 2, 2015. |
Extended European Search Report corresponding to EP 14 17 4814.5 dated Jun. 9, 2015. |
Australian Examination Report No. 1 corresponding to AU 2014200584 dated Jun. 15, 2015. |
European Office Action corresponding to EP 13 180 881.8 dated Jun. 19, 2015. |
European Office Action corresponding to EP 14 157 195.0 dated Jul. 2, 2015. |
Extended European Search Report corresponding to EP 12 19 6902.6 dated Aug. 6, 2015. |
Extended European Search Report corresponding to EP 14 15 2060.1 dated Aug. 14, 2015. |
Chinese Office Action corresponding to CN 201210129787.2 dated Aug. 24, 2015. |
Canadian Office Action corresponding to CA 2,665,206 dated Nov. 19, 2013. |
Chinese Notification of Reexamination corresponding to CN 201010517292.8 dated Jun. 2, 2015. |
Japanese Office Action corresponding to JP 2014-216989 dated Sep. 11, 2015. |
Canadian First Office Action corresponding to CA 2,686,105 dated Sep. 17, 2015. |
Japanese Office Action corresponding to JP 2012-040188 dated Oct. 21, 2015. |
European Communication corresponding to EP 13 17 6895.4 dated Nov. 5, 2015. |
Chinese First Office Action corresponding to CN 201210544552 dated Nov. 23, 2015. |
Chinese First Office Action corresponding to CN 201210545228 dated Nov. 30, 2015. |
Extended European Search Report corresponding to EP 15 18 0491.1 dated Dec. 9, 2015. |
Extended European Search Report corresponding to EP 15 18 3819.0 dated Dec. 11, 2015. |
Canadian Office Action corresponding to CA 2,697,819 dated Jan. 6, 2016. |
Canadian Office Action corresponding to CA 2,696,419 dated Jan. 14, 2016. |
European Office Action corresponding to EP 12 19 8776.2 dated Jan. 19, 2016. |
Extended European Search Report corresponding to EP 15 17 4146.9 dated Jan. 20, 2016. |
Chinese First Office Action corresponding to CN 201310353628.5 dated Jan. 25, 2016. |
Extended European Search Report corresponding to EP 12 19 6912.5 dated Feb. 1, 2016. |
Japanese Office Action corresponding to JP 2012-098903 dated Feb. 22, 2016. |
Extended European Search Report corresponding to EP 12 19 8753.1 dated Feb. 24, 2016. |
Chinese First Office Action corresponding to CN 201410449019.4 dated Mar. 30, 2016. |
Extended European Search Report corresponding to EP 16 15 0232.3 dated Apr. 12, 2016. |
European Office Action corresponding to EP 11 18 3256.4 dated Apr. 20, 2016. |
Australian Examination Report No. 1 corresponding to AU 2012244169 dated May 10, 2016. |
European Office Action corresponding to EP 10 25 0715.9 dated May 12, 2016. |
Chinese First Office Action corresponding to CN 201410778512.0 dated May 13, 2016. |
Australian Examination Report No. 1 corresponding to AU 2012227358 dated May 16, 2016. |
Japanese Office Action corresponding to JP 2012-040188 dated May 17, 2016. |
Australian Examination Report No. 1 corresponding to AU 2012244380 dated May 20, 2016. |
Australian Examination Report No. 1 corresponding to AU 2014227480 dated May 21, 2016. |
Australian Examination Report No. 1 corresponding to AU 2012254977 dated May 30, 2016. |
International Search Report and Written Opinion dated Sep. 30, 2022, issued in corresponding international application No. PCT/IB2022/055592, 12 pages. |
European Office Action corresponding to EP 14 17 2681.0 dated May 13, 2016. |
Extended European Search Report corresponding to EP 16 15 3647.9 dated Jun. 3, 2016. |
Chinese Office Action corresponding to CN 201210545228 dated Jun. 29, 2016. |
Japanese Office Action corresponding to JP 2012-250058 dated Jun. 29, 2016. |
European Office Action corresponding to EP 14 15 7997.9 dated Jun. 29, 2016. |
Canadian Office Action corresponding to CA 2,712,617 dated Jun. 30, 2016. |
Chinese First Office Action corresponding to CN 2013103036903 dated Jun. 30, 2016. |
Australian Patent Examination Report No. 1 corresponding to AU 2012250278 dated Jul. 10, 2016. |
Australian Patent Examination Report No. 1 corresponding to AU 2012244382 dated Jul. 10, 2016. |
Japanese Office Action corresponding to 2012-255242 dated Jul. 26, 2016. |
Japanese Office Action corresponding to JP 2012-268668 dated Jul. 27, 2016. |
European Office Action corresponding to EP 14 15 2060.1 dated Aug. 4, 2016. |
European Office Action corresponding to EP 12 16 5609.4 dated Aug. 5, 2016. |
European Office Action corresponding to EP 15 15 2392.5 dated Aug. 8, 2016. |
Japanese Office Action corresponding to JP 2013-003624 dated Aug. 25, 2016. |
Australian Patent Examination Report No. 1 corresponding to AU 2012261752 dated Sep. 6, 2016. |
Japanese Office Action corresponding to JP 2014-252703 dated Sep. 26, 2016. |
European Office Action corresponding to EP 12 19 8776.2 dated Sep. 12, 2016. |
Japanese Office Action corresponding to JP 2013-000321 dated Sep. 13, 2016. |
Chinese Second Office Action corresponding to CN 201310353628.5 dated Sep. 26, 2016. |
European Office Action corresponding to EP 12 15 2541.4 dated Sep. 27, 2016. |
Australian Patent Examination Report No. 1 corresponding to AU 2012268923 dated Sep. 28, 2016. |
Chinese First Office Action corresponding to CN 2013107068710 dated Dec. 16, 2016. |
Chinese First Office Action corresponding to CN 201310646606.8 dated Dec. 23, 2016. |
Japanese Office Action corresponding to JP 2013-000321 dated Jan. 4, 2017. |
Extended European Search Report corresponding to EP 16 16 6367.9 dated Jan. 16, 2017. |
Australian Examination Report No. 1 corresponding to AU 2013206777 dated Feb. 1, 2017. |
Chinese Second Office Action corresponding to CN 2013103036903 dated Feb. 23, 2017. |
Japanese Office Action corresponding to JP 2013-175379 dated Mar. 1, 2017. |
Chinese First Office Action corresponding to CN 201410028462.4 dated Mar. 2, 2017. |
Chinese First Office Action corresponding to CN 201410084070 dated Mar. 13, 2017. |
Extended European Search Report corresponding to EP 16 19 6549.6 dated Mar. 17, 2017. |
Japanese Office Action corresponding to JP 2013-147701 dated Mar. 21, 2017. |
Australian Examination Report No. 1 corresponding to AU 2013206804 dated Mar. 21, 2017. |
Australian Examination Report No. 1 corresponding to AU 2013211499 dated May 4, 2017. |
Australian Examination Report No. 1 corresponding to AU 2014201008 dated May 23, 2017. |
European Office Action corresponding to EP 15 17 4146.9 dated May 15, 2017. |
Japanese Office Action corresponding to JP 2013-154561 dated May 23, 2017. |
European Office Action corresponding to EP 12 19 4784.0 dated May 29, 2017. |
Japanese Office Action corresponding to JP 2013-169083 dated May 31, 2017. |
Australian Examination Report No. 1 corresponding to AU 2013213767 dated Jun. 29, 2017. |
Australian Examination Report No. 2 corresponding to AU 2012261752 dated Jul. 7, 2017. |
Australian Examination Report No. 1 corresponding to AU 2013266989 dated Jul. 10, 2017. |
Extended European Search Report corresponding to EP 14 15 3609.4 dated Jul. 14, 2017. |
Australian Examination Report No. 1 corresponding to AU 2013234418 dated Jul. 14, 2017. |
Extended European Search Report corresponding to EP 14 15 3610.2 dated Jul. 17, 2017. |
Australian Examination Report No. 1 corresponding to AU 2014200109 dated Jul. 20, 2017. |
Australian Examination Report No. 1 corresponding to AU 2014200074 dated Jul. 20, 2017. |
Japanese Office Action corresponding to JP 2013-250857 dated Aug. 17, 2017. |
Japanese Office Action corresponding to JP 2013-229471 dated Aug. 17, 2017. |
Australian Examination Report No. 1 corresponding to AU 2014200793 dated Sep. 2, 2017. |
Extended European Search Report corresponding to EP 17 17 8528.0 dated Oct. 13, 2017. |
Australian Examination Report No. 1 corresponding to AU 2013234420 dated Oct. 24, 2017. |
Japanese Office Action corresponding to JP 2013-175379 dated Oct. 20, 2017. |
Japanese Office Action corresponding to JP 2013-147701 dated Oct. 27, 2017. |
Extended European Search Report corresponding to EP 17 17 5656.2 dated Nov. 7, 2017. |
Japanese Office Action corresponding to JP 2014-009738 dated Nov. 14, 2017. |
European Office Action corresponding to EP 13 17 3986.4 dated Nov. 29, 2017. |
Japanese Office Action corresponding to JP 2017-075975 dated Dec. 4, 2017. |
European Office Action corresponding to EP 13 19 7958.5 dated Dec. 11, 2017. |
Chinese First Office Action corresponding to Patent Application CN 201410588811.8 dated Dec. 5, 2017. |
European Office Action corresponding to Patent Application EP 16 16 6367.9 dated Dec. 11, 2017. |
Chinese First Office Action corresponding to Patent Application CN 201610279682.3 dated Jan. 10, 2018. |
Japanese Office Action corresponding to Patent Application JP 2013-154561 dated Jan. 15, 2018. |
Australian Examination Report No. 1 corresponding to Patent Application AU 2017225037 dated Jan. 23, 2018. |
Japanese Office Action corresponding to Patent Application JP 2013-229471 dated May 1, 2018. |
Canadian Office Action corresponding to Patent Application CA 2,790,743 dated May 14, 2018. |
European Office Action corresponding to Patent Application EP 14 15 7195.0 dated Jun. 12, 2018. |
Extended European Search Report corresponding to Patent Application EP 12196912.5 dated Feb. 1, 2016. |
Chinese Second Office Action corresponding to Patent Application CN 201610279682.3 dated Aug. 8, 2018. |
Chinese Second Office Action corresponding to Patent Application CN 201410588811.8 dated Aug. 27, 2018. |
Extended European Search Report corresponding to Patent Application EP 18160809.2 dated Sep. 18, 2018. |
Extended European Search Report corresponding to Patent Application EP 18192317.8 dated Dec. 20, 2018. |
Extended European Search Report corresponding to Patent Application EP 18190154.7 dated Feb. 4, 2019. |
European Search Report corresponding to EP 06 00 4598, completed Jun. 22, 2006; (2 pp). |
European Search Report corresponding to EP 06 01 6962.0, completed Jan. 3, 2007 and dated Jan. 11, 2007; (10 pp). |
International Search Report corresponding to International Application No. PCT/US2005/036740, completed Feb. 20, 2007 and dated Mar. 23, 2007; (8 pp). |
International Search Report corresponding to International Application No. PCT/US2007/022713, completed Apr. 21, 2008 and dated May 15, 2008; (1 p). |
International Search Report corresponding to International Application No. PCT/US2008/002981, completed Jun. 9, 2008 and dated Jun. 26, 2008; (2 pp). |
European Search Report corresponding to EP 08 25 1779, completed Jul. 14, 2008 and dated Jul. 23, 2008; (5 pp). |
European Search Report corresponding to EP 08 25 1989.3, completed Mar. 11, 2010 and dated Mar. 24, 2010; (6 pp). |
European Search Report corresponding to EP 10 25 0639.1, completed Jun. 17, 2010 and dated Jun. 28, 2010; (7 pp). |
European Search Report corresponding to EP 10 25 0715.9, completed Jun. 30, 2010 and dated Jul. 20, 2010; (3 pp). |
European Search Report corresponding to EP 05 80 4382.9, completed Oct. 5, 2010 and dated Oct. 12, 2010; (3 pp). |
European Search Report corresponding to EP 09 25 2897.5, completed Feb. 7, 2011 and dated Feb. 15, 2011; (3 pp). |
European Search Report corresponding to EP 10 25 0642.5, completed Mar. 25, 2011 and dated Apr. 4, 2011; (4 pp). |
European Search Report corresponding to EP 12 15 2229.6, completed Feb. 23, 2012 and dated Mar. 1, 2012; (4 pp). |
European Search Report corresponding to EP 12 15 0511.9, completed Apr. 16, 2012 and dated Apr. 24, 2012; (7 pp). |
European Search Report corresponding to EP 12 15 2541.4, completed Apr. 23, 2012 and dated May 3, 2012; (10 pp). |
European Search Report corresponding to EP 12 16 5609.4, completed Jul. 5, 2012 and dated Jul. 13, 2012; (8 pp). |
European Search Report corresponding to EP 12 15 8861.0, completed Jul. 17, 2012 and dated Jul. 24, 2012; (9 pp). |
European Search Report corresponding to EP 12 16 5878.5, completed Jul. 24, 2012 and dated Aug. 6, 2012; (8 pp). |
Extended European Search Report corresponding to EP 12 19 1035.0, completed Jan. 11, 2013 and dated Jan. 18, 2013; (7 pp). |
Extended European Search Report corresponding to EP 12 18 6175.1, completed Jan. 15, 2013 and dated Jan. 23, 2013; (7 pp). |
Extended European Search Report corresponding to EP 12 19 1114.3, completed Jan. 23, 2013 and dated Jan. 31, 2013; (10 pp). |
Extended European Search Report corresponding to EP 12 19 2224.9, completed Mar. 14, 2013 and dated Mar. 26, 2013; (8 pp). |
Extended European Search Report corresponding to EP 12 19 6904.2, completed Mar. 28, 2013 and dated Jul. 26, 2013; (8 pp). |
Extended European Search Report corresponding to EP 12 19 6911.7, completed Apr. 18, 2013 and dated Apr. 24, 2013; (8 pp). |
Extended European Search Report corresponding to EP 07 00 5842.5, completed May 13, 2013 and dated May 29, 2013; (7 pp). |
Extended European Search Report corresponding to EP 12 19 8776.2, completed May 16, 2013 and dated May 27, 2013; (8 pp). |
Extended European Search Report corresponding to EP 12 19 8749.9, completed May 21, 2013 and dated May 31, 2013; (8 pp). |
Extended European Search Report corresponding to EP 13 15 6297.7, completed Jun. 4, 2013 and dated Jun. 13, 2013; (7 pp). |
Extended European Search Report corresponding to EP 13 17 3985.6, completed Aug. 19, 2013 and dated Aug. 28, 2013; (6 pp). |
Extended European Search Report corresponding to EP 13 17 3986.4, completed Aug. 20, 2013 and dated Aug. 29, 2013; (6 pp). |
Extended European Search Report corresponding to EP 13 17 7437.4, completed Sep. 11, 2013 and dated Sep. 19, 2013; 6 pages. |
Extended European Search Report corresponding to EP 13 17 7441.6, completed Sep. 11, 2013 and dated Sep. 19, 2013; (6 pp). |
Extended European Search Report corresponding to EP 07 86 1534.1, completed Sep. 20, 2013 and dated Sep. 30, 2013; (5 pp). |
Extended European Search Report corresponding to EP 13 18 3876.5, completed Oct. 14, 2013 and dated Oct. 24, 2013; (5 pp). |
Extended European Search Report corresponding to EP 13 17 1856.1, completed Oct. 29, 2013 and dated Nov. 7, 2013; (8 pp). |
Extended European Search Report corresponding to EP 13 18 0373.6, completed Oct. 31, 2013 and dated Nov. 13, 2013; (7 pp). |
Extended European Search Report corresponding to EP 13 18 0881.8, completed Nov. 5, 2013 and dated Nov. 14, 2013; (6 pp). |
Extended European Search Report corresponding to EP 13 17 6895.4, completed Nov. 29, 2013 and dated Dec. 12, 2013; (5 pp). |
Extended European Search Report corresponding to EP 13 18 2911.1, completed Dec. 2, 2013 and dated Dec. 16, 2013; (8 pp). |
Extended European Search Report corresponding to EP 10 25 1795.0, completed Dec. 11, 2013 and dated Dec. 20, 2013; (6 pp). |
Extended European Search Report corresponding to EP 13 18 7911.6, completed Jan. 22, 2014 and dated Jan. 31, 2014; (8 pp). |
Extended European Search Report corresponding to EP 13 19 2111.6, completed Feb. 13, 2014 and dated Feb. 27, 2014; (10 pp). |
Extended European Search Report corresponding to EP 13 19 5919.9, completed Feb. 10, 2014 and dated Mar. 3, 2014; (7 pp). |
Extended European Search Report corresponding to EP 08 72 6500.5, completed Feb. 20, 2014 and dated Mar. 3, 2014; (7 pp). |
Extended European Search Report corresponding to EP 13 19 5019.8, completed Mar. 14, 2014 and dated Mar. 24, 2014; (7 pp). |
Extended European Search Report corresponding to EP 13 19 6816.6, completed Mar. 28, 2014 and dated Apr. 9, 2014; (9 pp). |
Extended European Search Report corresponding to EP 13 19 7958.5, completed Apr. 4, 2014 and dated Apr. 15, 2014; (8 pp). |
Extended European Search Report corresponding to EP 13 19 4995.0, completed Jun. 5, 2014 and dated Jun. 16, 2014; (5 pp). |
Extended European Search Report corresponding to EP 14 15 7195.0, completed Jun. 5, 2014 and dated Jun. 18, 2014; (9 pp). |
Extended European Search Report corresponding to EP 14 15 6342.9, completed Jul. 22, 2014 and dated Jul. 29, 2014; (8 pp). |
Number | Date | Country | |
---|---|---|---|
20220409206 A1 | Dec 2022 | US |